Skip to main content

Table 3 Bone marrow lesion changes between interim visits

From: Structural effects of sprifermin in knee osteoarthritis: a post-hoc analysis on cartilage and non-cartilaginous tissue alterations in a randomized controlled trial

   100 μg cohort (n = 56) Mean (95 % CI) Matched placebo (n = 18) Mean (95 % CI) p - value
Whole knee Baseline 3.3 (2.5, 4.1) 3.3 (1.4, 5.2) 0.642
  Delta sum    
   0 to 3 months −0.02 (−0.38, 0.34) −0.17 (−0.85, 0.52) 0.682
   3 to 6 months −0.04 (−0.41, 0.34) −0.06 (−0.37, 0.26) 0.933
   6 to 12 months −0.14 (−0.54, 0.26) 0.44 (−0.15, 1.04) 0.054
  Delta subregion    
   0 to 3 months 0.02 (−0.28, 0.32) −0.22 (−0.87, 0.43) 0.597
   3 to 6 months −0.05 (−0.37, 0.27) −0.06 (−0.37, 0.26) 0.911
   6 to 12 months −0.14 (−0.48, 0.19) 0.44 (−0.15, 1.04) 0.042*
LTFJ Baseline 0.7 (0.3, 1.1) 0.7 (0.0, 1.4) 0.981
  Delta sum    
   0 to 3 months 0.04 (−0.12, 0.19) 0.00 (−0.17, 0.17) 0.859
   3 to 6 months 0.13 (−0.11, 0.36) −0.11 (−0.40, 0.18) 0.155
   6 to 12 months −0.13 (−0.39, 0.14) 0.22 (−0.10, 0.54) 0.062
  Delta subregion    
   0 to 3 months 0.04 (−0.12, 0.19) 0.00 (−0.17, 0.17) 0.859
   3 to 6 months 0.09 (−0.12, 0.30) −0.11 (−0.40, 0.18) 0.155
   6 to 12 months −0.05 (−0.27, 0.16) 0.22 (−0.10, 0.54) 0.064
MTFJ Baseline 1.6 (1.1, 2.2) 1.1 (0.3, 1.9) 0.418
  Delta sum    
   0 to 3 months −0.11 (−0.41, 0.20) −0.11 (−0.49, 0.27) 0.727
   3 to 6 months −0.07 (−0.27, 0.13) 0.06 (−0.21, 0.32) 0.530
   6 to 12 months 0.07 (−0.21, 0.35) 0.17 (−0.38, 0.71) 0.673
  Delta subregion    
   0 to 3 months −0.07 (−0.30, 0.16) −0.17 (−0.47, 0.14) 0.574
   3 to 6 months −0.05 (−0.21, 0.10) 0.06 (−0.21, 0.32) 0.525
   6 to 12 months 0.02 (−0.20, 0.24) 0.17 (−0.38, 0.71) 0.646
PFJ Baseline 1.0 (0.5, 1.5) 1.5 (0.1, 2.9) 1.000
  Delta sum    
   0 to 3 months 0.05 (−0.09, 0.20) −0.06 (−0.45, 0.34) 0.772
   3 to 6 months −0.09 (−0.24, 0.06) 0.00 (−0.24, 0.24) 0.647
   6 to 12 months −0.09 (−0.31, 0.13) 0.06 (−0.38, 0.49) 0.123
  Delta subregion    
   0 to 3 months 0.05 (−0.09, 0.20) −0.06 (−0.45, 0.34) 0.772
   3 to 6 months −0.09 (−0.24, 0.06) 0.00 (−0.24, 0.24) 0.647
   6 to 12 months −0.11 (−0.32, 0.10) 0.06 (−0.38, 0.49) 0.115
  1. CI confidence interval, LTFJ lateral tibio-femoral joint (includes 5 subregions), MTFJ medial tibio-femoral joint (includes 5 subregions), PFJ patello-femoral joint (includes 4 subregions). Possible score range for bone marrow lesion is 0–3 for each subregion at baseline, 3-, 6- and 12-month
  2. *Statistically significant at p ≤ 0.05